Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2203-97-6

Post Buying Request

2203-97-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2203-97-6 Usage

Chemical Properties

White or almost white, hygroscopic powder

Uses

Different sources of media describe the Uses of 2203-97-6 differently. You can refer to the following data:
1. Hydrocortisone 21-hemisuccinate is a corticosteroid used as an analytical and chromatography reagent.
2. glucocorticoid

Definition

ChEBI: A derivative of succinic acid in which one of the carboxy groups is esterified by the C-21 hydroxy group of cortisol (hydrocortisone).

Check Digit Verification of cas no

The CAS Registry Mumber 2203-97-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,0 and 3 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2203-97:
(6*2)+(5*2)+(4*0)+(3*3)+(2*9)+(1*7)=56
56 % 10 = 6
So 2203-97-6 is a valid CAS Registry Number.
InChI:InChI=1/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22?,23-,24-,25-/m0/s1

2203-97-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Hydrocortisone 21-hemisuccinate

1.2 Other means of identification

Product number -
Other names cortisol,hydrogensuccinate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2203-97-6 SDS

2203-97-6Synthetic route

succinic acid anhydride
108-30-5

succinic acid anhydride

HYDROCORTISONE
50-23-7

HYDROCORTISONE

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

Conditions
ConditionsYield
With pyridine at 20℃; for 24h;98%
With pyridine for 5h; Heating;94%
Stage #1: succinic acid anhydride; HYDROCORTISONE With dmap In tetrahydrofuran; N,N-dimethyl-formamide at 45℃; for 4h;
Stage #2: In tetrahydrofuran; N,N-dimethyl-formamide; acetone at 0 - 10℃; for 2h;
89%
succinic acid anhydride
108-30-5

succinic acid anhydride

HYDROCORTISONE
50-23-7

HYDROCORTISONE

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

Conditions
ConditionsYield
With pyridine at 20℃; for 24h;98%
With pyridine for 5h; Heating;94%
Stage #1: succinic acid anhydride; HYDROCORTISONE With dmap In tetrahydrofuran; N,N-dimethyl-formamide at 45℃; for 4h;
Stage #2: In tetrahydrofuran; N,N-dimethyl-formamide; acetone at 0 - 10℃; for 2h;
89%
4-nitro-phenol
100-02-7

4-nitro-phenol

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

hydrocortisone-21-O-β-carbonylpropionic acid p-nitrophenolic ester
147930-86-7

hydrocortisone-21-O-β-carbonylpropionic acid p-nitrophenolic ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; for 24h;95%
With dicyclohexyl-carbodiimide In tetrahydrofuran at 0 - 20℃; for 26h;95%
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

prednisolone-21-O-β-carbonylpropionyl-His-Gly-Lys-OH
757954-25-9

prednisolone-21-O-β-carbonylpropionyl-His-Gly-Lys-OH

Nα-(prednisolone-21-O-β-carbonylpropionyl)-His-Gly-Nε-(hydrocortisone-21-O-β-carbonyl-propionyl)-Lys-OH

Nα-(prednisolone-21-O-β-carbonylpropionyl)-His-Gly-Nε-(hydrocortisone-21-O-β-carbonyl-propionyl)-Lys-OH

Conditions
ConditionsYield
With 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; for 40h;74%
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

6--amino-2,3-dihydrophthalazine-1,4-dione
78544-61-3

6--amino-2,3-dihydrophthalazine-1,4-dione

cortisol-aminopentyl ethyl isoluminol conjugate
76773-85-8

cortisol-aminopentyl ethyl isoluminol conjugate

Conditions
ConditionsYield
With 1-hydroxy-pyrrolidine-2,5-dione; carbodiimide 1.) DMF, r.t., 2.) DMF, 4 h, r.t.; Multistep reaction;
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

HYDROCORTISONE
50-23-7

HYDROCORTISONE

Conditions
ConditionsYield
With tetramethyl ammoniumhydroxide; tetrazolium blue In ethanol Rate constant; Ambient temperature; reaction of corticosteroids and their hemisuccinate esters with blue tetrazolium under USP assay conditions, hydrolysis of esters, effect of water content, kinetic study by HPLC;
monophenylsulfonylfuroxan

monophenylsulfonylfuroxan

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

4-(4-benzenesulfonyl-5-oxy-furazan-3-yl)-4-oxo-butyric acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

4-(4-benzenesulfonyl-5-oxy-furazan-3-yl)-4-oxo-butyric acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
4-(2-hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-N-oxide

4-(2-hydroxyethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-N-oxide

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

succinic acid 2-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-ethyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

succinic acid 2-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-ethyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
1-methyl-3-[2-oxido-3-(phenylsulfonyl)-1,2,5-oxadiazol-4-yloxy]propan-1-ol

1-methyl-3-[2-oxido-3-(phenylsulfonyl)-1,2,5-oxadiazol-4-yloxy]propan-1-ol

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

succinic acid 3-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-1-methyl-propyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

succinic acid 3-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-1-methyl-propyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
4-(4-hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(4-hydroxybutoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

succinic acid 4-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-butyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

succinic acid 4-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-butyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
4-(2-(2-hydroxyethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(2-(2-hydroxyethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

succinic acid 2-[2-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-ethoxy]-ethyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

succinic acid 2-[2-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-ethoxy]-ethyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
4-(4-(hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(4-(hydroxymethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

succinic acid 4-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-benzyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

succinic acid 4-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-benzyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
4-(4-(2-hydroxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

4-(4-(2-hydroxyethyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

succinic acid 2-[4-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-phenyl]-ethyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

succinic acid 2-[4-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-phenyl]-ethyl ester 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide
186408-95-7

4-(2-aminoethoxy)-3-(benzenesulfonyl)-1,2,5-oxadiazole-2-oxide

N-[2-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-ethyl]-succinamic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

N-[2-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-ethyl]-succinamic acid 2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

hydrocortisone-21-O-β-carbonylpropionyl-Glu-Asp-Gly-OH

hydrocortisone-21-O-β-carbonylpropionyl-Glu-Asp-Gly-OH

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 95 percent / DCC / tetrahydrofuran / 26 h / 0 - 20 °C
2: 79 percent / N-hydroxysuccinimide; DCC / tetrahydrofuran / 40 h / 20 °C
View Scheme
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

hydrocortisone-21-O-β-carbonylpropionyl-His-Gly-Glu-OH

hydrocortisone-21-O-β-carbonylpropionyl-His-Gly-Glu-OH

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 95 percent / DCC / tetrahydrofuran / 26 h / 0 - 20 °C
2: 80 percent / N-hydroxysuccinimide; DCC / tetrahydrofuran / 40 h / 20 °C
View Scheme
hydrocortisone hemisuccinate
2203-97-6

hydrocortisone hemisuccinate

hydrocortison-21-O-succinyl-tyrosyl-arginine

hydrocortison-21-O-succinyl-tyrosyl-arginine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 95 percent / DCC / tetrahydrofuran / 24 h / 20 °C
2: 51 percent / HOBt; N-methyl morpholine / dimethylformamide / 48 h / 20 °C / pH 9
View Scheme

2203-97-6Relevant articles and documents

Preparation method of hydrocortisone sodium succinate

-

Paragraph 0042-0044; 0046-0048; 0050-0052; 0054-0056, (2019/10/02)

The invention discloses a preparation method of hydrocortisone sodium succinate. The method comprises the steps of preparing hydrocortisone succinic acid monoester by using succinic anhydride and hydrocortisone as raw materials; and performing a reaction by using the hydrocortisone succinic acid monoester as a raw material at a low temperature, and after the reaction is completed, performing treatment on the reaction liquid by adopting acetone with a temperature of about -20 DEG C to obtain the hydrocortisone sodium succinate. The process conditions adopted in the method provided by the invention are as follows: the sodium salt is generated at the low temperature, then the reaction liquid is added into a large amount of acetone, filtering is performed, the filter cake is washed by using the acetone and water, and finally vacuum drying is performed to remove the acetone; the process of high-temperature steaming is avoided, so that the product is stable, and has a high yield and a good state; the purity can reach 97% or more during reaction, and after purification, the product is in full compliance with the Chinese Pharmacopoeia standard; and the acetone can be recycled, so that theproduction costs are saved; therefore, the solution is suitable for industrial production, and the product quality is good.

Magnetic particle-based hydrocortisone chemiluminescence immune assay method and kit

-

Paragraph 0015; 0054-0056, (2018/07/30)

The invention discloses a fully-automatic magnetic particle-based hydrocortisone chemiluminescence immune assay method and application thereof. Immunomagnetic beads are coated by goat anti rabbit, antigen is detected by a chemiluminescent marker, a specific antibody of hydrocortisone is applied, a competitive response mode is established, a fully-automatic chemiluminescence immune assay serves asa detection tool, and the hydrocortisone is quantitatively detected according to the measured luminous value. According to the established method, the maximal detection range of the hydrocortisone reaches to 0.42 to 72.27 ng/mL, the detection limit is 0.12 ng/mL, the sensitivity can reach to 5.57 ng/mL and the recovery rate is 84.3 to 102.3 percent. According to the method, the detection process can realize full automation, the influence by professional testing personnel is not considered, the whole detection process is rapid and can be completed only by about 40 minutes, the detection limit is low, the sensitivity is high, the linear range is wide, the market requirement is met and good market application prospect is achieved.

The synthesis and immunosuppressive activities of steroid-urotoxin linkers

Wang, Chao,Zhao, Ming,Qiu, Xuecai,Peng, Shiqi

, p. 4403 - 4421 (2007/10/03)

The urotoxins (Glu-Asp-Gly-OH, His-Gly-Glu-OH, His-Gly-Lys-OH, and His-Gly-Lys-NHNH2) were introduced into the convenient sites of hydrocortisone and prednisolone via the amidation or condensation reactions to form the corresponding linkers 7a-d, 8a-d, 9a,b, and 10a,b in acceptable yields. The bioassays such as prolongation of heterotopic transplanted cardiac tissue survival in vivo, inhibitory effects on phagocytosis of mouse peritoneal macrophages and concanavalin (ConA) or lipopolysaccharide (LPS) induced proliferation of mouse spleen lymphocytes in vitro show that at the comparable concentrations the immunosuppressive activities of the steroid-urotoxin linkers 7a-d, 8a-d, 9a,b, and 10a,b were higher than that of hydrocortisone, prednisolone, and the urotoxins alone, as well as significantly higher than that of the mixture of hydrocortisone and urotoxins or prednisolone and urotoxins. The so-called 'permissive action' may be responsible for the enhancement of the mentioned bioactivities of the steroid-urotoxin linkers 7a-d, 8a-d, 9a,b, and 10a,b.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2203-97-6